top of page

'Haytox' not a solution for hayfever

The Therapeutic Goods Administration (TGA) is aware of a product known as 'Haytox,' which is being promoted as a remedy for nasal allergies, such as hayfever.

'Haytox' has not received TGA approval and is not listed in the Australian Register of Therapeutic Goods (ARTG).

The TGA has not conducted an assessment of this product and therefore advises consumers that it cannot assure the product's quality, safety, or effectiveness. Consumers should also be aware of the potential for severe side effects when using medications for an unapproved purpose.

The TGA underscores to healthcare providers the importance of providing accurate information about a product's safety and effectiveness. It has come to our attention that 'Haytox' may contain botulinum toxin (botox). Although the TGA has approved specific botox-containing products, 'Haytox' lacks approval and has not been assessed for treating hayfever.

Promoting therapeutic goods not listed on the ARTG to the general public, or in a manner inconsistent with their ARTG entry, such as for an alternative medical use, is against the law. It is also typically illegal to advertise prescription-only substances or goods, including compounded medicines.

These products are not authorised for marketing or sale in Australia.

There are legal consequences associated with advertising and distributing these products. Importing, exporting, manufacturing, or supplying these products is unlawful and may result in legal action.

For clinics utilising Haytox products or advertising them to clients, the TGA advises becoming acquainted with the legal stipulations of the advertising code and the regulations regarding prescription medicine distribution.

The TGA possesses the authority to take action against illicit health product advertising, including online advertising. Advertising a prescription medicine unlawfully in Australia can lead to imprisonment and fines of up to $1.565 million for individuals and $15.65 million for corporations.

23 views0 comments


bottom of page